[20050308]RS21418_植物性药品监管.pdf

1 This sections sources include the Biotechnology Industry Organization, Pew Initiative on Foodand Biotechnology, and CRS Issue Brief IB10131, Agricultural Biotechnology: Overview andSelected Issues. Contacts: Tadlock Cowan (7-7600) on agricultural and USDA aspects of thisreport; Donna Vogt (7-7285) on medical, food safety, and Food and Drug Administration aspects.2 Personal communication with Legislative and Public Affairs Office, USDAs Animal and Plant(continued.)Congressional Research Service The Library of CongressCRS Report for CongressReceived through the CRS WebOrder Code RS21418Updated March 8, 2005Regulation of Plant-Based Pharmaceuticals Geoffrey S. BeckerResources, Science, and Industry DivisionDonna VogtDomestic Social Policy DivisionSummaryAmong many genetically engineered crops being developed are a number modifiedto produce pharmaceutical compounds (none yet commercialized). Proponents say suchplant-based proteins could be produced more cheaply than by conventional methods andeconomically benefit farmers. But critics see risks, such as potential environmental,food safety, and trade problems. Among the issues is whether the current system forregulating biotechnology i